Last reviewed · How we verify
MM120 (LSD D-Tartrate)
MM120 is a formulated version of LSD (lysergic acid diethylamide) that acts as a serotonin 5-HT receptor agonist, particularly at 5-HT1A and 5-HT2A receptors, to modulate neural circuits involved in mood and perception.
MM120 is a formulated version of LSD (lysergic acid diethylamide) that acts as a serotonin 5-HT receptor agonist, particularly at 5-HT1A and 5-HT2A receptors, to modulate neural circuits involved in mood and perception. Used for Major depressive disorder (in development).
At a glance
| Generic name | MM120 (LSD D-Tartrate) |
|---|---|
| Sponsor | Definium Therapeutics US, Inc. |
| Drug class | Serotonergic psychedelic / 5-HT agonist |
| Target | 5-HT1A, 5-HT2A, 5-HT7 receptors |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | Phase 3 |
Mechanism of action
LSD binds to and activates serotonin receptors throughout the brain, with particular affinity for 5-HT2A receptors in cortical regions. This activation is thought to promote neuroplasticity and alter default mode network activity, potentially facilitating therapeutic psychological insights and emotional processing. The D-tartrate salt formulation improves stability and bioavailability for clinical use.
Approved indications
- Major depressive disorder (in development)
Common side effects
- Perceptual disturbances / hallucinations
- Anxiety
- Elevated blood pressure
- Tachycardia
- Mydriasis (pupil dilation)
Key clinical trials
- A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) (PHASE3)
- A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) (PHASE3)
- A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) (PHASE3)
- A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms (PHASE2)
- Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MM120 (LSD D-Tartrate) CI brief — competitive landscape report
- MM120 (LSD D-Tartrate) updates RSS · CI watch RSS
- Definium Therapeutics US, Inc. portfolio CI